Interleukin-13 (IL-13) and IL-4 are related multifunctional cytokines with similar biological activities on human B cells and monocytes. [1] [2] [3] [4] [5] [6] [7] The cognate receptors for these cytokines are complex and have been shown to share 2 chains with each other. [8] [9] [10] [11] [12] The IL-4 receptor system is well characterized and has been shown to be composed of a primary IL-4 binding protein, IL-4R␣ (also known as IL-4R␤). 13 This chain forms a heterodimer with either the IL-2R␥ c chain (type I IL-4R) or IL-13R␣1 (also known as IL-13R␣Ј) (type II IL-4R) for signaling. 11, [14] [15] [16] [17] In some situations, all 3 chains (IL-4R␣, IL-2R␥ c , and IL-13R␣1) may constitute the IL-4R complex; however, whether all 3 chains are simultaneously required for IL-4 function is not known.
Introduction
Interleukin-13 (IL-13) and IL-4 are related multifunctional cytokines with similar biological activities on human B cells and monocytes. [1] [2] [3] [4] [5] [6] [7] The cognate receptors for these cytokines are complex and have been shown to share 2 chains with each other. [8] [9] [10] [11] [12] The IL-4 receptor system is well characterized and has been shown to be composed of a primary IL-4 binding protein, IL-4R␣ (also known as IL-4R␤). 13 This chain forms a heterodimer with either the IL-2R␥ c chain (type I IL-4R) or IL-13R␣1 (also known as IL-13R␣Ј) (type II IL-4R) for signaling. 11, [14] [15] [16] [17] In some situations, all 3 chains (IL-4R␣, IL-2R␥ c , and IL-13R␣1) may constitute the IL-4R complex; however, whether all 3 chains are simultaneously required for IL-4 function is not known.
In contrast, the receptor for IL-13 is less well characterized. We have studied the structure of IL-13R in various cell types and reported that IL-13 binds to 2 isoforms of an approximate 65-kDa protein in human renal cell carcinoma cells. [8] [9] [10] [11] [12] One of these proteins also binds IL-4. 8, 14 On the basis of the binding characteristics, cross-linking, and displacement of radiolabeled IL-4 and IL-13 in various cell types, we hypothesized that, as is the case for the IL-4R system, IL-13R may also be composed of 3 different types. [9] [10] [11] [12] More recently, 2 different chains of the IL-13R system have been cloned. The murine and human IL-13R␣1 chain was first cloned. 14, 18 This chain can bind IL-13 with low affinity, but, when coupled with the IL-4R␣ chain, the heterodimer binds IL-13 with high affinity and mediates IL-13-induced signaling. 14, 18 The second chain of the IL-13R, termed IL-13R␣2 (also known as IL-13R␣), has also been cloned from a human renal cell carcinoma cell line (Caki-1). This chain shares approximately 50% homology with the IL-5R at the DNA level. It contains a very short intracellular domain and binds IL-13 with high affinity. 19 On the basis of the above studies, we have proposed that the type I IL-13R complex is composed of both chains of IL-13R (IL-13R␣1 and IL-13R␣2) and IL-4R␣ chain. Although IL-13 binds to all 3 chains, only the IL-13R␣1 and IL-4R␣ chains form a productive complex. Because of this arrangement, IL-13 binds to these cells strongly. Only IL-13, not IL-4, is able to displace the binding of 125 I-IL-13. In the type II IL-13R system, IL-13R␣2 is not present, and the IL-13R␣1 chain forms a complex with the IL-4R␣ chain. In these cells both interleukins compete for the binding of their radiolabeled cognaters. 12 The structure of the type III IL-13R is similar to that of type II receptors except that these cells also express the IL-2R␥ c chain. Although it appears that the IL-2R␥ c chain does not bind IL-13, it does affect IL-13 binding and function in some cell types. 20, 21 After binding to their receptors, both IL-4 and IL-13 signal through phosphorylation-dependent activation of Jak kinases and signal transduction and activator of transcription (STAT) protein. 11, 17, 22 In particular, STAT6 is activated in response to both IL-4 and IL-13. 17, 22, 23 In the IL-4R system, activation of STAT6 protein was seen in cells transfected with IL-13R␣1 chain and IL-4R␣ chain; however, no activation was observed in cells transfected with the IL-13R␣2 chain alone or when transfected with IL-4R␣ chain. 15 Whether IL-13 induces STAT6 activation by similar combination of receptor subunits is not known. It is also not known whether the IL-13R␣2 chain plays a major role in IL-13 functions. It has been reported that the extracellular domain of IL-13R␣2 is secreted in the plasma and urine of mice. However, in the context of human physiology, this protein has not been identified. 24, 25 To determine the function of IL-13R␣2, this chain was transfected either alone or in combination with other known chains of the IL-4R and IL-13R systems in Chinese hamster ovary (CHO-K1) cells and T98G glioblastoma cells. Transfectants were studied to determine whether (1) IL-13R is internalized after binding to 125 I-IL-13, (2) the intracellular domain of IL-13R␣2 plays a role in ligand internalization, (3) IL-13 can transmit signals in cells that are transfected with this chain, and (4) a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin (termed IL13-PE38QQR) 26, 27 is cytotoxic to cells that are transfected with the IL-13R␣2 chain. Our studies demonstrate, for the first time, that IL-13R␣2 can be internalized after binding to IL-13 without inducing intracellular signaling through the STAT6 pathway.
Materials and methods

Recombinant cytokines and toxins
Recombinant human IL-13 1,5 was produced and purified to homogeneity in our laboratory (B. H. Joshi and R.K.P., unpublished results). 28 Recombinant IL13-PE38QQR was also produced and purified in our laboratory (Joshi et al, unpublished results). The cpIL4-toxin IL4 38-37 -PE38KDEL, containing the circularly permuted IL-4 mutant in which amino acids 38-129 were linked to amino acids 1-37 via a GGNGG linker and then fused to truncated toxin PE38KDEL, consisting of amino acids 253-364 and 381-608 of PE followed by KDEL, was expressed in Escherichia coli and purified as described previously. 29, 30 Cell lines CHO-K1 and human glioblastoma multiforma cell lines (T98G) were purchased from the American Type Culture Collection (Rockville, MD). CHO-K1 cells were cultured in a modified Eagle minimum essential medium (AMEM), and T98G cells were cultured in Eagle minimum essential medium (EMEM) containing 10% fetal bovine serum (Biowhittaker, Walkersville, MD), 1 mmol HEPES, 1 mmol L-glutamine, 100 g/mL penicillin, and 100 g/mL streptomycin (Biowhittaker).
Plasmids, mutagenesis, and transient transfection of DNA
Complementary DNAs (cDNAs) of human IL-4R␣ chain, 13 IL-13R␣2 chain, 19 and IL-13R␣1 chain 14 were cloned into pME18S mammalian expression vector [pIL4R␣, pIL13R␣ (␣2), and pIL13R␣Ј (␣1)]. The IL-13R␣ deletion mutants ⌬335L, ⌬338R, or ⌬343Y were constructed by the polymerase chain reaction (PCR), using Taq DNA polymerase with the primer 5Ј-CCGCTCGAGATGGCTTTCGTTTGCTTGGCTATCGG-3Ј and 3Ј-GCTCTAGATCAACCGGTTACAAATATAACTAATATTAAG-5Ј (⌬335L) or 3Ј-GCTCTAGATCACAAAAGCAGACCGGTTACAA-ATATAAC-5Ј (⌬338R) or 3Ј-GCTCTAGATCAGGTGTTTGGCTTACG-CAAAAG-5Ј (⌬343Y), each containing an in-frame stop codon. The cDNAs were subcloned into the expression vector pCIneo, using the XhoI and XbaI sites. Individual plasmid DNA or a combination of multiple plasmid DNAs (6 g/60-mm dish or 12 g/100-mm culture dish) were transfected into semiconfluent cells, using GenePORTER transfection reagent (Gene Therapy Systems, San Diego, CA) according to the manufacturer's instructions. Briefly, cells (1 ϫ 10 6 /60-mm dish or 3 ϫ 10 6 /100-mm dish) were incubated with the DNA-GenePORTER mixture for 5 hours in Dulbecco modified Eagle medium (DMEM; Biowhittaker). Then DMEM containing 20% fetal bovine serum (FBS) was added, and incubation was continued. Twenty-four hours after transfection, the medium was changed to AMEM (CHO-K1) or EMEM (T98G) with 10% FBS, and cells were incubated for and an additional 24 hours.
Radioreceptor binding assay
Recombinant human IL-13 was labeled with 125 I (Amersham, Arlington Heights, IL), using IODO-GEN reagent (Pierce, Rockford, IL) as previously described. 8 The specific activity of the radiolabeled IL-13 was estimated to be 12.7 Ci/g protein. For binding experiments, 5 ϫ 10 5 cells in 100 L binding buffer (RPMI 1640 containing 0.2% human serum albumin and 10 mmol HEPES) were incubated with 200 pmol 125 I-IL-13 with or without 40 nmol unlabeled IL-13 at 4°C for 2 hours. Cell-bound 125 I-IL-13 was separated from unbound by centrifugation through a phthalate oil gradient, and radioactivity was determined with a gamma counter (Wallac, Gaithersburg, MD). For the displacement assay, T98G cells were incubated with 125 I-IL-13 (200 pmol) with or without increasing concentration (up to 100 nmol) of IL-13, as described above.
IL-13R internalization
Internalization assays were performed as described before. 21 CHO-K1 or T98G cells with or without transfected IL-13R␣ chain were incubated in binding buffer containing 0.2 nmol chloroquine at 37°C for 5 minutes to prevent degradation of internalized 125 I-IL-13. The cells were then washed, and 2 ϫ 10 7 cells were incubated with 0.5 nmol 125 I-IL-13 at 4°C for 2 hours. At various time intervals, 2 duplicate sets of 50 L aliquots were taken. One set was incubated with glycine buffer (final pH ϭ 2.0) for 10 minutes on ice. The suspension was then centrifuged through a mixture of phthalate oils, and the radioactivity in the cell pellet (acid-resistant or internalized) and in the supernatant (surface-bound plus dissociated) was determined with a gamma counter. The other set of 50-L aliquots was directly centrifuged through phthalate oils, and the radioactivity observed in the supernatants was used for dissociated 125 I-IL-13 values. Surface-bound 125 I-IL-13 was determined by subtracting dissociated 125 I-IL-13 values from surface-bound plus dissociated values.
Protein synthesis inhibition assay
The cytotoxic activity of IL-13 toxin or IL-4 toxin was tested as previously described. 27 Typically, 10 4 cells were cultured in leucine-free medium with or without various concentrations of IL13-PE38QQR or IL4 38-37 -PE38KDEL for 20 to 22 hours at 37°C. Then 1 Ci of [ 3 H]leucine (NEN Research Products, Boston, MA) was added to each well and incubated for an additional 4 hours. Cells were harvested, and radioactivity incorporated into cells was measured by a beta plate counter (Wallac).
Electrophoretic mobility shift assay
After incubation with IL-13 (250 ng/mL) for 10 minutes, cells were washed with cold extraction buffer (1 mg/mL leupeptin, 5 mg/mL pepstatin A, 2 mg/mL aprotinin, 20 mmol HEPES pH 7.0, 10 mmol KCl, 300 mmol NaCl, 0.5 mmol dithiothreitol [DTT], 0.1% NP-40, 1 mmol phenylmethylsulfonyl fluoride, 1 mmol Na 3 VO 4 , and 20% glycerol). DNA protein interactions were assessed by electrophoretic mobility shift assay (EMSA), using a Bandshift kit (Pharmacia, Piscataway, NJ). Briefly, 50 g sample proteins was incubated in 20 L binding buffer [10 mmol Tris-HCl (pH 7.5), 50 mmol NaCl, 0.5 mmol DTT, 10% glycerol, 0.05% NP-40, 0.05 mg/mL poly (dI-dC) 2 ] for 20 minutes at room temperature with 1 ng 32 P-labeled double-stranded oligonucleotide probe SBE1. SBE1 is a STAT-binding element (5Ј-gatcGCTCTTCTTCCCAGGAACTCAATG-3Ј; 3Ј-CGAGAAG AAGGGTCCTTGAGTTACagct-5Ј) that is from the region flanking the transcription start site of the human sIL-1R antagonist gene that is necessary for response to IL-13. 31 Ten times concentrated loading dye (2 L) was added to samples that were then applied to a 4% nonreducing polyacrylamide gel and run at 150 V for 2.5 hours. Gels were dried for 2 hours and autoradiographed overnight at room temperature.
For the supershift assay, antihuman STAT6 (S-20) rabbit polyclonal immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA) was included in the reaction mixture before electrophoresis.
Results
I-IL-13 binding on CHO-K1 or T98G cells transfected with IL-13R␣2, IL-13R␣1, and IL-4R␣ chains
To demonstrate ligand binding and directly examine the subunit structure of IL-13R, cDNAs of various human IL-13R chains were introduced into the CHO-K1 cell line, and binding studies were performed. As shown in Figure 1A Figure 2B and C, IL-13 bound to IL-13R␣2-transfected T98G cells with strong affinity (Kd ϭ 1.12 nmol/L), and the receptor number was estimated to be approximately 30 580 sites/cell. These results suggest that IL-13R␣2 chain binds IL-13 with high affinity.
Internalization of IL-13R on CHO-K1 and T98G cells transfected with the IL-13R␣2 chain
To determine whether the IL-13R␣2 chain when expressed alone can be internalized after binding to its ligand, IL-13, we examined the rate of internalization and disappearance of surface-bound IL-13 using 125 I-IL-13. As shown in Figure 3 , CHO-K1 and T98G cells transfected with IL-13R␣2 chain bound IL-13, and the level of surface-bound 125 I-IL-13 steadily declined with time in both CHO-K1 cells and T98G cells. Concurrently, the level of 125 I-IL-13 internalized increased in these cells. In CHO-K1 cells transfected with the IL-13R␣2 chain, the level of internalization was higher compared to control vector-transfected cells. IL-13R␣2 chain-transfected cells showed an approximately 35% higher internalization level at 90 minutes when compared to control CHO-K1 cells ( Figure 3A) . Interestingly, control CHO-K1 cells also showed internalization of IL-13, indicating that these cells express functional IL-13R and that hamster cells bind human IL-13. However, in T98G cells, vector-transfected control cells showed no internalization, and 100% of the IL-13 remained surface bound even after 2 hours of incubation at 37°C. However, IL-13R␣2 chain transfectants showed a remarkable level of internalization that reached to maximum of approximately 80% of total bound ligand at 120 minutes ( Figure 3B ). These results suggest that, on binding to ligand 125 I-IL-13, the IL-13R␣2 chain is internalized at a high rate and IL-13R␣2 is required for internalization.
Cytotoxicity of IL13-PE38QQR on CHO-K1 cells transfected with the IL-13R␣2, IL-13R␣1, and IL-4R␣ chains
To further confirm whether the IL-13R chain is internalized after binding to ligand, the cytotoxicity of a recombinant IL13-PE38QQR targeting IL-13R was assessed. IL13-PE38QQR binds to IL-13R and is internalized by endocytosis, subsequently causing For personal use only. on September 13, 2017. by guest www.bloodjournal.org From apoptotic and/or necrotic cell death through the inhibition of new protein synthesis. 32, 33 Thus, cytotoxicity observed in transfected cells indicates receptor internalization. CHO-K1 cells were transfected with the IL-13R␣2 chain in the absence or presence of other IL-13R chains, and sensitivity to IL13-PE38QQR was determined. As shown in Figure 4A , when CHO-K1 cells were transfected with IL-13R␣2 alone, IL13-PE38QQR was highly cytotoxic to these cells. The 50% inhibitory concentration (IC 50 ; IL-13 toxin concentration causing 50% inhibition of protein synthesis) ranged between 7 and 10 ng/mL. When CHO-K1 cells were transfected with the IL-13R␣1 chain alone, no cytotoxicity was observed even when 1000 ng/mL IL-13 toxin was added (data not shown). However, when CHO-K1 cells were transfected with the IL-4R␣ chain, 25% cytotoxicity was seen at 100 ng/mL IL-13 toxin ( Figure 4A ). Similar to binding data (Figure 1 ), when the ␣2 chain was cotransfected with the IL-13R␣1 or IL-4R␣ chains, the cytotoxicity was similar to that seen with ␣2 chain transfection alone ( Figure  4B) . However, when all 3 chains (IL-4R␣, IL-13R␣, and ␣2) were cotransfected, cytotoxic activity was slightly increased compared to ␣2␣1 or ␣2 IL-4R␣ transfectants (IC 50 of 10 ng/mL compared to 30 ng/mL in ␣1␣2 IL-4R␣ or ␣1␣2 transfectants, respectively). Cells transfected with the ␣1 and IL-4R␣ chains showed little sensitivity to IL13-PE38QQR.
We next examined whether sensitivity to IL-13 toxin was IL-13R␣2 concentration dependent. To address this point, we transfected CHO-K1 cells with various amounts of IL-13R␣2 cDNA and examined the cytotoxicity of IL13-PE38QQR. As shown in Figure 4C , increasing protein synthesis inhibition was observed as the amounts of cDNA used for transfection increased. When more than 3 g IL-13R␣2 cDNA was transfected in CHO-K1 cells, the protein synthesis was inhibited by 50% with less than 100 ng/mL IL13-PE38QQR. At the highest concentration of DNA (6 g), maximum sensitivity to IL13-PE38QQR was observed (IC 50 ϭ 4 ng/mL).
To confirm whether the cytotoxicity of IL13-PE38QQR was mediated through IL-13R, IL-13R␣2-transfected cells were tested for sensitivity to IL-4 toxin, IL4 38-37 -PE38KDEL as well as IL13-PE38QQR. As shown in Figure 4D , CHO-K1 cells transfected with IL-13R␣2 chain were highly sensitive to IL-13 toxin but not to IL4 38-37 -PE38KDEL even when up to 1000 ng/mL recombinant toxin was used. These results correspond to our previous findings, indicating that the IL-4R system does not utilize the IL-13R␣2 chain. [9] [10] [11] 15 IL-4 toxin was cytotoxic to CHO-K1 cells when transfected with IL-4R␣ alone or in combination with ␥ c chain. However, control cells and cells transfected with ␥ c chain alone were not killed by IL-4 toxin ( Figure 4E ).
Role of intracellular domain of IL-13R␣2 in ligand internalization
To examine the role of the intracellular domain of the IL-13R␣2 chain in the internalization process, we made deletions in the intracellular domain of ␣2 chain ( Figure 5A ). After transient transfection of these deletion mutant genes in CHO-K1 cells, we performed IL-13 binding and internalization studies. As shown in Figure 5B , deletion of the part of transmembrane domain and whole intracellular domain (⌬335L mutant) caused a significant decrease in IL-13 binding. In addition, this deletion mutant showed no sensitivity to IL-13-PE38QQR similar to control cells ( Figure  5C ). These results indicate that the part of transmembrane domain and/or all of intracellular domain of IL-13R␣2 are required for IL-13 internalization. However, deletions of part or complete intracellular domain alone (⌬338R or ⌬343Y) showed no change in IL-13 binding or sensitivity to IL-13 toxin. Therefore, it was concluded that amino acids between L335 and Y343 in the IL-13R␣2 chain might be involved in IL-13 binding and/or internalization.
Activation of STAT6 in response to IL-13 in IL-13R chain transfectants
To demonstrate whether the IL-13R␣2 chain signals after binding IL-13 and whether IL-13R␣1 and IL-4R␣ by themselves or heterodimers with the IL-13R␣2 chain are biologically functional, we analyzed STAT6 activation in response to IL-13 in various IL-13R chain transfectants. As shown in Figure 6A (lane 1), no T98G (B) cells were incubated with 0.5 nmol 125 I-IL-13 at 4°C for 2 hours. Then the temperature was raised to 37°C, and, at various time intervals, 2 duplicate sets of 50 L aliquots were taken. One set was incubated with glycine buffer (pH ϭ 2.0) for 10 minutes. The mixture was then centrifuged through phthalate oils, and the radioactivity in the cell pellet (internalized) and in the supernatant (surface-bound plus dissociated) was determined with a gamma counter. The other set of 50 L aliquots was directly centrifuged through phthalate oils, and the radioactivity observed in the supernatant was used for dissociated 125 STAT6 activation was observed in CHO-K1 cells transfected with the IL-13R␣2 chain. However, when cells were transfected with ␣1 or IL-4R␣ chains, low-level activation was observed ( Figure 6A , lanes 2 and 3). When the ␣1 chain was cotransfected with the IL-4R␣ chain, the STAT6 activation was induced to its highest level ( Figure 6A, lane 8) . Cotransfection of the ␣2 chain with the IL-4R␣ chain or ␣1 chain did not induce STAT6 activation. In fact, ␣2 chain transfection abrogated IL-4R␣ or ␣1-induced STAT6 activation ( Figure 6A, lanes 5 and 6) . In addition, when ␣ 1 , IL-4R␣, ␣1␥ c , and IL-4R␣␥ c were cotransfected with the ␣2 chain, the STAT6 activation was decreased ( Figure 6A, lanes 11-13) . CHO-K1 To further study the impact of the IL-13R␣2 chain on STAT6 activation, we transfected CHO-K1 cells with the ␣1 and IL-4R␣ chains along with various amounts of ␣2 chain cDNA. As shown in Figure 6B , the extent of STAT6 activation in response to IL-13 was gradually decreased as the amount of ␣2 chain cDNA transfected increased. We also assessed the effect of the IL-13R␣2 chain in IL-13-induced STAT6 activation in CHO-K1 cells transfected with IL-4R␣, IL-13R␣1, and ␥ c chains. As shown in Figure 6C , introduction of the IL-13R␣2 chain at very high concentration can still inhibit IL-13-induced STAT6 activation as seen in IL-4R␣ and IL-13R␣1 transfectants. The presence of ␥ c chain had no effect on this inhibition.
To confirm whether the IL-13-induced SBE-1-binding complex contains STAT6, an antibody supershift assay was performed. The STAT6 activation that was induced by IL-13 in ␣1 IL-4R␣ heterodimer transfectants showed a substantial supershift by anti-STAT6 antibody ( Figure 6D , lane 2). These data confirm that SBE-1 binding complexes induced by IL-13 contain the STAT6 molecule.
Discussion
The major goal of our study was to investigate whether the IL-13R␣2 chain can internalize IL-13 ligand by itself and whether this chain can induce signal transduction through STAT pathways. In this report, we demonstrate that the IL-13R␣2 chain can bind with high affinity to IL-13 and can promote internalization of ligand, but it cannot induce signaling via the STAT6 pathway. Although we cannot rule out the possibility that IL-13 may signal through different signaling cascades, our results suggest an interesting dissociation between internalization and signal transduction by IL-13R. This phenomenon is similar to that observed for the IL-6 receptor system in which IL-6 signal transducer gp130 is internalized without inducing signal transduction through the JAK/STAT pathway. 34, 35 The IL-13R␣2 chain affects a decrease in the level of IL-13-induced STAT6 activation in cells cotransfected with the IL-13R␣1 and IL-4R␣ chains or IL-13R␣1, IL-4R␣, and ␥ c chain. This decrease in signaling may be due in part to the "stealing" of IL-13 from other components of the receptor, thus making less IL-13 available for binding and signaling through type II IL-13 receptors.
The internalization of ligand on IL-13R␣2 transfection alone was also confirmed by cytotoxicity assays that utilize IL-13 cytotoxin. CHO-K1 cells transfected with the IL-13R␣2 chain were very sensitive to recombinant IL13-PE38QQR cytotoxin in a doseand IL-13R␣2 concentration-dependent manner. However, IL-4 toxin was not cytotoxic, indicating specificity of the internalization. When IL-13R␣2 chain was cotransfected with IL-13R␣1 and IL-4R␣ chains, a slightly higher cytotoxicity was observed. These results agree with the binding studies and further indicate that IL-13 toxin is internalized through the IL-13R␣2 chain that, when combined with the IL-13R␣1 and IL-4R␣ chains, produces an additive effect.
It is of interest that about 25% protein synthesis inhibition occurs at 100 ng/mL and higher concentrations of IL13-PE38QQR in CHO-K1 cells transfected with the IL-4R␣ chain alone. Because CHO-K1 cells express low levels of specific IL-13R, transfection of the IL-4R␣ chain may form functional type II IL-13 complex, resulting in internalization of IL13-PE38QQR.
It has been demonstrated that a di-leucine motif in the intracellular domain of type I cytokine receptor systems (eg, IL-6R, 35, 36 granulocyte colony-stimulating factor receptor, 37 epidermal growth factor receptor, 38 growth hormone receptor, 39 and human insulin receptor 40 ) plays an essential role in the internalization of ligand. In the IL-13R␣2 chain, there is no intracellular domain L-L motif; however, 3 residues, L335, L336, and L337, are present at the carboxy terminus of the transmembrane domain. 19 Whether these leucine residues interact with other amino acids and contribute to the internalization of IL13-IL-13R complex is not known. To study this, we produced 3 deletion mutants in the intracellular domain of the IL-13R␣2 chain, and the significance of different intracellular mutants was examined by binding and internalization studies. From these studies, it was concluded that amino acids between L335 and Y343 play a role in IL-13 binding and/or internalization.
We found that when CHO-K1 cells were transduced with IL-13R␣1 or IL-4R␣ chain cDNA, a modest activation of STAT6 was observed. It is possible that CHO-K1 cells naturally express IL-4R␣ and IL-13R␣1 chains and on introduction of either of these chains form a functional IL-13R complex. To address this issue, we performed reverse transcriptase (RT)-PCR analysis of these chains. Although we did not find expression of these chains by sensitive RT-PCR assay (data not shown), we do not rule out the possibility of their expression because (1) CHO-K1 cells specifically bind IL-13 and (2) primers used in our study were designed to amplify human receptor chain RNA. The specific primers for Chinese hamster may be needed to reverse transcribe and detect hamster receptor chains. Alternatively, the IL-13R␣1 and IL-4R␣ chains can homodimerize on binding to IL-13 albeit at low levels and can activate STAT6. Homodimerization of IL-4R␣ has been shown to activate STAT6 on stimulation with IL-4. 15 In conclusion, we have reconstituted a functional IL-13R by transfecting various components of the IL-13R system. For the first time we provide experimental evidence that the IL-13R␣2 chain is a functional component of an IL-13R system that promotes binding and internalization of ligand. In addition, the IL-13R␣2 chain may interact with the ␣1 or IL-4R␣ chains, or both, as it inhibits the effect of IL-13 on STAT6 activation in ␣1-or IL-4R␣-transfected cells. Since IL-13R␣2 is not involved in type II or type III IL-13R systems commonly expressed on normal immune and some nonimmune cells, our observations indicate that the IL-13R␣2 chain can be a potential target for receptor-directed immunotherapy or gene therapy for cancer or inflammatory diseases in which the IL-13R is involved. In addition, transfer of the IL-13R␣2 chain gene may make cells more susceptible to the cytotoxic effect of IL-13 toxin.
